Related Funds
Fund Name | Location |
1to1 Venture Partners | Connecticut, Stamford, United States |
DIG Investments | Apache Junction, Arizona, United States |
Elephant Capital | England, London, United Kingdom |
Elscint Biomedical Investment | - |
EVA Basel | Basel, Basel-Stadt, Switzerland |
Garnett Ventures | California, San Francisco, United States |
Hebei Technology Investment Group | China, Hebei, Shijiazhuang |
Invictus Advisory Group | - |
Kiwi II Venture Capital | - |
LNB group | India, Kolkata, West Bengal |
Pacific Eagle Asset Management | California, San Ramon, United States |
Porsche Digital | Germany, Ludwigsburg, Mecklenburg-Vorpommern |
Portal Software | California, Cupertino, United States |
SINBON Electronics | Taipei, Taiwan |
Sowefund | France, Ile-de-France, Paris |
Special Equities Group | - |
The Artemis Fund | Houston, Texas, United States |
Yangli Konggu | China, Liaoning, Shenyang |
Zhekong Jincheng | Beijing, Beijing, China |
Notable deals
Company | Industry | Round Size | Date | Investors | Location |
Merrimack Pharmaceuticals | $28M | 05 May 2004 | Cambridge, Massachusetts, United States |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Latest deals
Company | Industry | Round Size | Date | Investors | Location |
Merrimack Pharmaceuticals | $28M | 05 May 2004 | Cambridge, Massachusetts, United States |